Interleukins 

  Products    Products    Diseases    News 


«12...89101112131415161718...15281529»
  • ||||||||||  Impact of Pre-Existing Mental Health Disorders (MHD) on CAR T-Cell Therapy Outcomes in Patients with Large B-Cell Lymphoma (Halls G-H (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_3035;    
    380 (86%) received axicabtagene ciloleucel, 42 (10%) received lisocabtagene maraleucel, 19 (4%) received tisagenlecleucel...Patients with MHD had a higher incidence of grade ?3 CRS (19% vs. 9.4%, p=0.0040) and grade ?3 ICANS (51% vs. 26%, p<0.0001), as well as higher use of anakinra (14% vs. 5%, p=0.0019) and corticosteroids (65% vs. 46%, p=0.0001) for CAR-T related toxicity...This data supports access to CAR-T for patients with MHD and underscore the need for integrated psychiatric care and close monitoring to reduce adverse events. Future research should assess if targeted interventions can mitigate CAR-T related toxicity in patients with MHD.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Tecartus (brexucabtagene autoleucel) / Gilead, Yescarta (axicabtagene ciloleucel) / Gilead
    Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma (Halls G-H (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_3034;    
    Data from this single-institution experience suggest the use of prophylactic steroids accompanying CART during treatment of R/R NHL may delay onset of CRS without adversely affecting overall clinical outcomes. Larger cohort studies and/or randomized control trials will be required to confirm these findings.
  • ||||||||||  WU-NK-101 / Wugen
    WUN101-01: First in Human Human (FIH) Phase 1 Study of WU-NK-101 (W-NK1) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) (Halls G-H (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_3001;    
    P1
    Cytokine Release Syndrome was reported in 4 (44.4%) pts, all G1, typically occurring the day of first or second infusion, a median duration of 2 days, and managed to complete resolution with antipyretics +/- tocilizumab...Overall, W-NK1 has demonstrated a tolerable and manageable safety profile with preliminary evidence of anti-tumor activity. Furthermore, our study highlights the evolution, expansion, and persistence of W-NK1 in patients with AML, suggesting W-NK1 as a best-in-class NK cell therapy.
  • ||||||||||  Elzonris (tagraxofusp-erzs) / Menarini
    Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Na (Halls G-H (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_2882;    
    P1/2
    Conclusions As demonstrated previously, TAG offers rapid and durable responses in front-line treated BPDCN patients. The observed safety profile, lack of cumulative myelosuppression, and restoration of normal hematopoiesis with TAG treatment support the efficacy and tolerability of TAG as monotherapy for BPDCN and makes TAG a safe and promising combination partner for treatment of other CD123+ hematologic malignancies.
  • ||||||||||  Elzonris (tagraxofusp-erzs) / Menarini
    Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results (Halls G-H (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_2842;    
    This therapy is currently only available in selected countries and only 3 out of the 13 countries participating in this registry reported its use. The treatment strategy of BPDCN should be a total therapy approach incorporating novel agents like tagraxofusp with intrathecal chemotherapy and allo-SCT to prevent the relapse.
  • ||||||||||  Istodax (romidepsin) / Astellas, BMS
    Romidepsin, Azacitidine, Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-Cell Lymphoma (Pacific Ballroom Salons 15-17 (Marriott Marquis San Diego Marina)) -  Nov 6, 2024 - Abstract #ASH2024ASH_2462;    
    P1
    Multiagent targeted therapy with RAdR is safe in r/r TCL and induces a high rate of response, particularly at the MTD, but durable complete responses are uncommon without consolidation. The four-drug regimen is active across the diverse spectrum of TCL subtypes and may be an effective therapeutic bridge to transplantation.
  • ||||||||||  hydroxyurea / Generic mfg., decitabine / Generic mfg., pomalidomide / Generic mfg.
    A Novel Small Molecule Drug-Based Approach for Treating Beta-Globinopathies (Room 31 (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_2411;    
    Synergistic effects with Decitabine were notable, showing a 4-fold increase in mRNA expression compared to SH6 alone and a 9-fold increase compared to Decitabine alone. Additionally, SH6 demonstrated the unique ability to reactivate more "primitive" forms of globins, epsilon and zeta globins, suggesting potential relevance for treating both alpha and beta thalassemia.
  • ||||||||||  Sylvant (siltuximab) / Jazz, Rituxan (rituximab) / Roche
    Burden of Idiopathic Multicentric Castleman Disease (iMCD) in the US: A Population-Level Real World Analysis Using a Health-Claims Dataset (Room 6B (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_2356;    
    Larger randomized studies are needed to confirm and expand on our results. Results from this analysis reveal 1) a discordance in the number of iMCD cases identified using different approaches, supporting the notion that using a health-claims dataset to study the epidemiology of iMCD is challenging, 2) an algorithm relying on use of the CD-specific ICD-10 code in conjunction with the minor criteria consistent with international diagnostic guidelines2 and exclusion of CD mimics likely provides the most accurate pool of iMCD patients, 3) siltuximab use was dismally low at 22%, indicating high unmet treatment need and 4) the use of a non-FDA approved therapy rituximab was observed in 16%, indicating divergence from clinical guidelines in routine clinical practice.
  • ||||||||||  lenalidomide / Generic mfg.
    Impact of Thrombosis and Bleeding on Survival of Older People with Myelodysplastic Syndromes (MDS): A Population Analysis (Room 6CF (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_2350;    
    While this could be due baseline differences in comorbidity and MDS risk, it could also result from the consequences of bleeding versus VTE on clinical management, with bleeding events more significantly impacting use of disease-modifying therapy such as HMA. We identified risk factors for VTE and bleeding, which may help refine risk assessment and potentially preventing these adverse events.
  • ||||||||||  Yescarta (axicabtagene ciloleucel) / Gilead
    Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) (Pacific Ballroom Salons 24-26 (Marriott Marquis San Diego Marina)) -  Nov 6, 2024 - Abstract #ASH2024ASH_2313;    
    P2, P3
    Introduction In the Phase 3 ZUMA?7 study (NCT03391466), axi-cel, an autologous anti-CD19 CAR T-cell therapy, showed superior event-free survival (EFS; Locke FL, et al...Lymphodepleting chemotherapy regimens were mostly cyclophosphamide plus fludarabine (75%) or bendamustine (22%)...To treat pts with any CRS and/or ICANS (n=398, 89%), tocilizumab, corticosteroids, and anakinra were given to 80%, 65%, and 18%, respectively...Despite a broader pt population beyond the ZUMA-7 and ALYCANTE trials, outcomes at median follow-up of 12 mo were consistent with those observed in ZUMA-7. DCL, SK, and MSOB contributed equally.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Yescarta (axicabtagene ciloleucel) / Gilead
    Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma (Pacific Ballroom Salons 24-26 (Marriott Marquis San Diego Marina)) -  Nov 6, 2024 - Abstract #ASH2024ASH_2311;    
    Conclusion This study represents the largest evaluation to date of outcomes of CD19CAR in tiNHL, and demonstrates that CAR is highly effective with an acceptable toxicity profile in tiNHL pts. Thus, CAR may be able to overcome the historically poor prognosis associated with conventional therapies for tiNHL.
  • ||||||||||  lenalidomide / Generic mfg., cyclophosphamide / Generic mfg., carfilzomib / Generic mfg.
    Final Analysis of the Randomised UK MRA Myeloma XI+ Trial Examining Krdc (carfilzomib, lenalidomide, dexamethasone and cyclophosphamide) As Induction Therapy for Newly Diagnosed Multiple Myeloma Patients (Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)) -  Nov 6, 2024 - Abstract #ASH2024ASH_2172;    
    KRdc was given in 28 day cycles (carfilzomib (K) 36mg/m2 IV d1-2, 8-9,15-16 (20mg/m2 #1d1-2), lenalidomide (R) 25mg PO d1-21, dexamethasone (d) 40mg PO d1-4,8-9,15-16, cyclophosphamide (C) 500mg PO d1,8), CRd (28d, C 500mg PO d1,8, R 25mg PO d1-21, D 40mg PO d1-4, 12-15) and CTd (21d, C 500mg PO d1,8,15 thalidomide 100-200mg PO daily, D 40mg PO d1-4,12-15)...Suboptimal responders (MR/PR) to CTd/CRd were randomized between pre-transplant intensification with a proteasome inhibitor (bortezomib, CVD) containing triplet or no further therapy prior to ASCT, patients with refractory disease (SD/PD) all received CVD...OS was significantly improved when including non-contemporaneous controls, adjusted for temporal trends. This suggests a clinically significant improvement in overall survival and emphasises the importance of early combination of PI and IMID therapy rather than a response adapted approach, with particular benefit in patients with aggressive disease defined as HiR or UHiR.
  • ||||||||||  Tecvayli (teclistamab-cqyv) / Genmab, J&J
    Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial (Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)) -  Nov 6, 2024 - Abstract #ASH2024ASH_2156;    
    Tec-Len demonstrated deepening of responses and 100% MRD negative CR rate at 12 mo in Cohort 1 evaluable pts. Daratumumab, a CD38-targeting monoclonal antibody, has shown deep and durable responses and prolonged survival outcomes in combination with lenalidomide and dexamethasone (DRd) and in combination with bortezomib plus lenalidomide and dexamethasone (DVRd), in patients with NDMM...In Cycles 2+, Tec 1.5 mg/kg was given QW in Arm A and 3.0 mg/kg Q4W in Arms A1 and B. SC daratumumab (1800 mg) was administered QW in Cycles 1-2 and Q2W in Cycles 3-6...Among the 23 patients who completed stem cell mobilization, median stem cell yield was 8.7
  • ||||||||||  dexamethasone / Generic mfg., lenalidomide / Generic mfg.
    Implications of MRD Progression in Newly Diagnosed Multiple Myeloma (NDMM) Treated with Quadruplet Therapy and Autologous Stem Cell Transplantation (San Diego Ballroom AB (Marriott Marquis San Diego Marina)) -  Nov 6, 2024 - Abstract #ASH2024ASH_2137;    
    Understanding the implication of increasing MRD burden is particularly relevant in patients with NDMM treated with quadruplet therapy (QUAD, consisting of a PI, an IMiD, an anti-CD38 mAb and dexamethasone) and autologous stem cell transplantation (ASCT), since most will reach MRD negativity...Among the 19 patients with MRD-P, 12 (63%) were on observation at time of MRD-P, 2 were receiving single agent lenalidomide, 5 were receiving a QUAD, 17 (89%) had previously obtained MRD negativity at <10-5 including 10 (53%) who had also achieved MRD negativity at 10-6...Outcomes of patients with MRD-P are similar to those of patients with IMWG-defined PD. These findings challenge the paradigm of IMWG-defined PD and paraprotein measurability as minimal parameters for change in therapy and introduction of agents with new mechanisms of action.
  • ||||||||||  lenalidomide / Generic mfg.
    653. Multiple Myeloma: Clinical and Epidemiological: Advancing Minimal Residual Disease (MRD): Detection, Impact on Prognosis and Treatment Decisions (San Diego Ballroom AB (Marriott Marquis San Diego Marina)) -  Nov 6, 2024 - Abstract #ASH2024ASH_2134;    
    In addition, the session also examines the clinical significance of peripheral residual disease beyond conventional MRD measurements in the bone marrow; the use of single-cell whole-genome sequencing to study circulating tumor cells in relapsed/refractory MM, and the utility of soluble B-cell maturation antigen levels for monitoring disease in oligo- and non-secretory MM. Collectively, these studies highlight advancements in understanding MRD and its potential as a key marker for guiding treatment strategies and improving patient outcomes in multiple myeloma.